

Grant Support (Since UAMS Appointment)

	PI	Co-I	Mentor	Pending	In Prep
Extramural		2		1 (PI)	2 (in prep)
Foundation	8	4	1		
Industry	13				
Intramural	1		2	1 (PI)	

Current Grants (Direct Costs)

2016-2018	Metabolic biomarkers in people with Down Syndrome
\$1,000,000	Down's Syndrome Foundation, Little Rock, Co-Principal Investigator, 10% Effort
2016-2019	Treating Gastrointestinal and Autism Symptoms in Adults with Autism Using Microbiota Transfer Therapy
\$500,000	Department of Defense, Fort Detrick, MD, Co-PI, 10% Effort
2013-2016	Folate receptor autoimmunity in autism spectrum disorders
\$250,000	Autism Speaks, New York NY, Co-Investigator, No Paid Effort
2014-2016	Effectiveness of Early Intensive Behavioral Intervention Services for Children with Autism Spectrum Disorders
\$50,000	Autism Treatment Network, Boston, MA, Co-investigator, 3% Effort
2015-2016	Mitochondrial dysfunction and autism: Inflammatory subtype
\$45,000	Autism Research Institute, San Diego, CA, Co-PI, No Paid Effort
2014-2016	Effectiveness of Services for Children with Autism Spectrum Disorders
\$25,000	National Institute of Child Health and Development, Co-investigator, 3% Effort
2015-2016	Mitochondrial Dysfunction in Autism Spectrum Disorder
\$20,000	Autism Research Institute, San Diego, CA, Principal Investigator, No Paid Effort

Current Industry Research

2016-2018	Treating Gastrointestinal Symptoms in Children with Autism Using Microbiota Transfer Therapy.
\$440,258	Crestovo LLC, Greenwich, CT. Co-investigator, 35% Effort
2016	Effect of AIMs and HSP90 inhibitors on in vitro mitochondrial respiration in control and autism lymphoblastoid cell lines
\$30,000	Reata Pharmaceuticals, Inc, Irving TX. Principal Investigator, 5% Effort
2016	Phytocannabinoids protective effect on oxidative stress induced mitochondrial dysfunction in control and autistic cell lines
\$162,000	GW Pharmaceuticals, Cambridge, UK, Principal Investigator, 10% Effort

2015-2016	A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin
\$136,925	Curemark, LLC, Rye, NY. Site Investigator, Per Subject
2016-2017	A Open-Label Extension Study of CM-AT for the Treatment of Autism in Children.
\$211,900	Curemark, LLC, Rye, NY. Site Investigator, Per Subject
2015-2017	CAMP-01: Children's Autism Metabolome Project (CAMP): Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood
\$409,505	Stemina Biomarker Discovery, Inc., Madison, WI. Site Investigator, Per Subject

Pending Grants

2016-2021	A High-dose Folinic Acid Treatment for Core and Associated Symptoms of Autism. Scored 11%ile
\$2,476,681	National Institute of Child Health and Development, PI, 35% Effort